DAJO Bio Raises Tens of Millions of RMB in Seed Financing to Advance Next-Generation TCR Protein Therapies
Shenzhen-based biotechnology startup DAJO Bio (“DAJO”) has completed a seed financing round worth tens of millions of RMB, providing fresh capital to advance its next-generation T-cell receptor (TCR) protein therapeutic platforms and pipeline…
Biokin’s Iza-bren hits Phase 3 PFS endpoint in EGFR-Mutant NSCLC, marking 4th positive Phase 3 trial
Sichuan Biokin Pharmaceutical’s izalontamab brengitecan (iza-bren, BL-B01D1) has achieved another major clinical milestone, with the company reporting that its Phase 3 BL-B01D1-301 study in previously treated EGFR-mutant non-small cell lung cancer…
Henlius Expands Sandoz Partnership in Up to $322 Million Biosimilars Deal
Shanghai Henlius Biotech, Inc. (“Henlius”) has significantly expanded its partnership with Sandoz, entering a strategic collaboration covering up to 10 monoclonal antibody (mAb) and antibody-drug conjugate (ADC) biosimilar candidates in a…
MagicRNA raises hundreds of millions of yuan in Series B financing to advance world’s first in vivo CAR-T therapy
Recently, Shenzhen MagicRNA Biotechnology Co., Ltd. (or MagicRNA) announced the completion of a Series B financing round of several hundred million yuan. This round was led by a fund under CICC Capital, co-led by Kangjun Capital , with participation from…
Keymed completed Phase 2 trial of CM512, a TSLP x IL-13 bispecific antibody for chronic sinusitis
The Phase II clinical trial of long-acting TSLP x IL-13 bispecific antibody CM512 for the treatment of chronic sinusitis with nasal polyps (CRSwNP) has met all study endpoints.
GenFleet launches world’s first Phase 3 study of an oral KRAS G12D inhibitor for the treatment of NSCLC
GenFleet Therapeutics today held a national investigator conference for its Phase III registrational clinical trial of GFH375 (an oral KRAS G12D inhibitor) as monotherapy for non-small cell lung cancer (NSCLC) (“Kylin-Flight 01”). “Kylin-Flight 01” is a…
Aiming at an ‘Undruggable” target, Pyrotech’s class 1 small-molecule candidate gets approved for sepsis clinical trials
On August 4, Pyrotech Therapeutics (“Pyrotech”) announced that its independently developed small-molecule pyroptosis inhibitor, PTT-121, has been approved for clinical trials in China, intended for the treatment of sepsis and septic shock.…
Alphamab Oncology and Pathos reach international licensing agreement for TROP2/HER3 bispecific ADC.
On August 4, Alphamab Oncology (“Alphamab”) announced a licensing agreement with Pathos AI (“Pathos”) for its proprietary, “First-in-Class” TROP2/HER3 bispecific antibody-drug conjugate (ADC), JSKN016. Under the…
Kelun Biotech seeks marketing approval on sac-TMT for the first-line treatment of PD-L1-negative TNBC
On July 30, 2026, Sichuan Kelun Biotech Co., Ltd. (“Kelun”) announced that its independently developed antibody-drug conjugate (ADC) targeting human trophoblast surface antigen 2 (TROP2), sac-TMT (also known as SKB264/MK-2870) (Gitalay®), has…